Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Kymriah Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of TennesseePolicy ID_CHS_22942026_1126

    Tisagenlecleucel (Kymriah®) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_22942026_1126 alerts

    Get alerted when Policy ID_CHS_22942026_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for tisagenlecleucel (Kymriah) for specified pediatric, young adult, and adult B-cell leukemias and lymphomas. Coverage requires applicable clinical criteria, documentation, and absence of listed exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyTisagenlecleucel (Kymriah®) Coverage Criteria
    Policy CodePolicy ID_CHS_22942026_1126
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation confirming the applicable indication-specific criteria and absence of coverage exclusions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsAuthorization duration
    1 doseDose per course
    2+ linesPrior therapy for adult lymphoma
    Under 26Pediatric ALL age limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CD19-positive
    Required tumor marker

    Covered Indications and Exclusions

    Pediatric and young adult relapsed or refractory B-cell ALL

    Covered for a 3-month authorization for one dose when all of the following are met.

    Pediatric and young adult B-cell precursor ALL

    • Disease and tumor criteria

      • CD19 expression: Member has CD19 tumor expression in bone marrow or peripheral blood
      • Bone marrow disease burden: Member has at least 5% lymphoblasts in the bone marrowat least 5%
    • Disease status

      • Philadelphia chromosome-negative disease: Member has Philadelphia chromosome-negative disease that is refractory or has had 2 or more relapsesRefractory or 2 or more relapses
      • Philadelphia chromosome-positive disease

        • Ph-positive disease conditions

          • Refractory disease: Member has refractory disease
          • Multiple relapses with TKI failure: Member has had 2 or more relapses and has failed at least 2 tyrosine kinase inhibitorsAt least 2 TKIs
          • TKI intolerance: Member has relapsed disease and is TKI intolerant
          • Post-HSCT relapse: Member has experienced a relapse after hematopoietic stem cell transplant
    • Age and performance status: Member is less than 26 years of age and has a Karnofsky performance status of at least 50% if age 16 or older, or a Lansky performance status of at least 50% if younger than 16Age less than 26 years; performance status >=50%

    Adult B-cell lymphomas

    Covered for a 3-month authorization for one dose when all of the following are met.

    Adult B-cell lymphoma eligibility

    • Age: Member is 18 years of age or olderAge >=18 years
    • Qualifying lymphoma subtype

      • Diffuse large B-cell lymphoma arising from follicular lymphoma
      • Follicular lymphoma
      • Histologic transformation of an indolent lymphoma to diffuse large B-cell lymphoma

    ALK-positive large B-cell lymphoma

    Covered for a 3-month authorization for one dose.

    Relapsed/refractory ALK-positive large B-cell lymphoma

    • ALK positivity: Disease is ALK-positive large B-cell lymphoma
    • CD19 expression: Tumor is CD19-positive

    Histologic Richter transformation to DLBCL

    Covered for a 3-month authorization for one dose when the applicable alternative criterion is met.

    • Disease-specific pathway

      • Clonally unrelated or previously untreated CLL: Disease is clonally unrelated, or the member has previously untreated chronic lymphocytic leukemia, with partial response, refractory disease, or progression on chemoimmunotherapy
      • Clonally related or unknown clonal status: Disease is clonally related or has unknown clonal status in a member with previously treated chronic lymphocytic leukemia, with partial response, refractory disease, or progression on prior systemic therapy

    Relapsed/refractory ALK-positive large B-cell lymphoma

    Authorization of three months for one dose may be granted for treatment of relapsed or refractory ALK-positive large B-cell lymphoma when all of the following are met.

    ALK-positive large B-cell lymphoma eligibility

    • Member is 18 years of age or olderAge >=18 years
    • Member has relapsed or refractory ALK-positive large B-cell lymphoma
    • Disease is CD19-positiveCD19-positive disease

    Specified relapsed/refractory B-cell lymphomas

    For the specified relapsed or refractory B-cell lymphoma indications, all of the following requirements must be met.

    Specified B-cell lymphoma eligibility

    • Eligible disease

      • Diffuse large B-cell lymphoma
      • High-grade B-cell lymphoma, including double/triple hit lymphoma or high-grade B-cell lymphoma not otherwise specified
      • HIV-related B-cell lymphoma, including HIV-related diffuse large B-cell lymphoma, primary effusion lymphoma, HHV8-positive diffuse large B-cell lymphoma not otherwise specified, or plasmablastic lymphoma
      • Monomorphic post-transplant lymphoproliferative disorder, B-cell type

    Histologic Richter transformation to DLBCL

    Authorization of three months for one dose may be granted for histologic Richter transformation to DLBCL in members 18 years of age or older when either of the following criteria is met.

    Richter transformation eligibility

    • Member is at least 18 years old and has histologic Richter transformation to diffuse large B-cell lymphomaAge >=18 years
    • Disease-specific pathway

      • Clonally unrelated or previously untreated CLL pathway: Disease is clonally unrelated, or the member has previously untreated chronic lymphocytic leukemia, and the disease has partial response, refractory disease, or progression on chemoimmunotherapyPartial response, refractory disease, or progression on chemoimmunotherapy
      • Previously treated CLL pathway:

    Tennessee off-label indication requirement

    For off-label indications of FDA-approved drugs, coverage complies with the Tennessee statutory requirement when the following criterion is met.

    Tennessee off-label coverage standard: The off-label use is recognized in one of the statutorily recognized standard reference compendia or in published peer-reviewed medical literatureRecognition in an applicable compendium or peer-reviewed literature

    Requirement under Tennessee Code Annotated Section 56-7-2352.

    Primary central nervous system lymphoma is not an indicated use of tisagenlecleucel (Kymriah) and is not eligible for coverage.

    Coverage will not be provided when the member has received a previous treatment course with tisagenlecleucel or another CD19-directed chimeric antigen receptor (CAR) T-cell therapy.

    Coverage will not be provided for members with inadequate and unstable kidney, liver, pulmonary, or cardiac function.

    Coverage will not be provided for members with active or latent hepatitis B, active hepatitis C, or any active uncontrolled infection.

    Coverage will not be provided for members with active graft-versus-host disease or an active inflammatory disorder.

    For the specified adult B-cell lymphoma indications, the member must not have primary central nervous system lymphoma. Coverage may be denied when this diagnosis is present.

    Indications other than the listed FDA-approved and compendial uses are considered experimental/investigational and not medically necessary.

    Clinical Thresholds and Status Requirements

    Bone marrow lymphoblasts
    Minimum bone marrow lymphoblastsAt least 5%
    Applicable conditionB-cell precursor acute lymphoblastic leukemia in members less than 26 years of age
    Required confirmationTesting or analysis confirming at least 5% lymphoblasts in the bone marrow
    Karnofsky or Lansky performance status
    Required performance statusKarnofsky or Lansky performance status greater than or equal to 50%
    Karnofsky appliesMembers age 16 years or older
    Lansky applies

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Kymriah. Coverage is available only when the applicable indication-specific criteria are met and the member has no listed exclusion.

    • Review and document all applicable clinical eligibility criteria before submitting the authorization request.
    • Authorization applies only to the covered indications described in this policy.
    Prior Authorization

    Three-Month, One-Dose Authorization

    When approved, authorization is limited to a three-month treatment period and one dose for the applicable pediatric ALL, adult B-cell lymphoma, ALK-positive large B-cell lymphoma, and Richter transformation indications.

    • Pediatric and young adult B-cell precursor ALL: members younger than 26 years.
    • Adult B-cell lymphomas, relapsed/refractory ALK-positive large B-cell lymphoma, and histologic (Richter) transformation to DLBCL: members 18 years of age or older.

    Therapy Overview

    Tisagenlecleucel (Kymriah) is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy used for selected B-cell malignancies, including pediatric B-cell acute lymphoblastic leukemia and specified B-cell lymphomas. Coverage is limited to eligible disease settings, including relapsed or refractory disease and listed compendial uses, and is subject to clinical requirements and exclusions.

    Clinical Definitions

    High-grade B-cell lymphoma with translocations
    Disease classificationHigh-grade B-cell lymphoma with translocations
    TranslocationsMYC and BCL2 and/or BCL6
    Also calledDouble/triple hit lymphoma
    ECOG performance status 0 to 2
    ECOG range0 to 2
    Self-careAmbulatory and capable of all self-care
    Activity limitationUnable to carry out work activities and up and about more than 50% of waking hours

    Initial Therapy Decision Criteria

    Initial therapy for pediatric and young adult B-cell ALL

    Authorization of 3 months for one dose may be granted when all of the following criteria are met.

    Initial pediatric and young adult B-cell ALL therapy

    • Member is less than 26 years of ageAge less than 26 years
    • Member has CD19 tumor expression in bone marrow or peripheral blood
    • Member has at least 5% lymphoblasts in the bone marrowAt least 5%
    • Disease status

    Required Prior Therapy

    StepConditionRequirement
    1Philadelphia chromosome-positive B-cell ALL with two or more relapsesFailure of at least two tyrosine kinase inhibitors (TKIs), such as asciminib, bosutinib, dasatinib, imatinib, nilotinib, or ponatinib

    Authorization Duration and Dose

    Tisagenlecleucel (Kymriah)
    DrugTisagenlecleucel (Kymriah)
    Quantity limitOne dose per treatment course
    Authorization period3 months
    Tisagenleucel (Kymriah)
    DrugTisagenlecleucel (Kymriah)
    Dose quantityOne dose
    Applied perTreatment course
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyTisagenlecleucel (Kymriah®) Coverage Criteria
    Policy CodePolicy ID_CHS_22942026_1126
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation confirming the applicable indication-specific criteria and absence of coverage exclusions.
    SourceLink
    On This Page
    Covered Indications and ExclusionsClinical Thresholds and Status RequirementsAuthorization, Documentation, and Denial RisksTherapy OverviewClinical DefinitionsInitial Therapy Decision CriteriaRequired Prior TherapyAuthorization Duration and Dose
    Diffuse large B-cell lymphoma
  1. High-grade B-cell lymphoma, including high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or BCL6 (double/triple hit lymphoma), or high-grade B-cell lymphoma not otherwise specified
  2. HIV-related B-cell lymphoma, including HIV-related diffuse large B-cell lymphoma, primary effusion lymphoma, HHV8-positive diffuse large B-cell lymphoma not otherwise specified, or plasmablastic lymphoma
  3. Monomorphic post-transplant lymphoproliferative disorder, B-cell type
  4. Prior therapy: Member has received prior treatment with two or more lines of systemic therapy2 or more lines
  5. Central nervous system lymphoma exclusion: Member does not have primary central nervous system lymphoma
  6. Performance status: Member has an ECOG performance status of 0 to 2ECOG 0 to 2
  7. Prior systemic therapy: Member has received prior treatment with two or more lines of systemic therapyAt least 2 prior systemic therapy lines
  8. Central nervous system lymphoma exclusion: Member does not have primary central nervous system lymphoma
  9. Performance status: Member has an ECOG performance status of 0 to 2ECOG 0 to 2
  10. Disease is clonally related or has unknown clonal status in a member with previously treated chronic lymphocytic leukemia, and the disease has partial response, refractory disease, or progression on prior systemic therapy
    Partial response, refractory disease, or progression on prior systemic therapy
    Members younger than 16 years
    ECOG performance status
    Required ECOG range0 to 2
    Functional capacityAmbulatory and capable of all self-care, but unable to carry out any work activities
    Activity levelUp and about more than 50% of waking hours
    Age for pediatric and young adult B-cell ALL
    Age thresholdLess than 26 years of age
    DiseaseB-cell precursor acute lymphoblastic leukemia
    Authorization3 months for one dose when all applicable criteria are met
    Philadelphia chromosome-negative disease
    Disease statusPhiladelphia chromosome-negative disease must be refractory or have had 2 or more relapses
    Relapse threshold2 or more relapses
    Applicable treatmentTisagenlecleucel coverage for pediatric and young adult B-cell precursor ALL
    Philadelphia chromosome-positive disease
    Relapse threshold2 or more relapses
    TKI requirementFailure of at least 2 tyrosine kinase inhibitors
    Other qualifying pathwaysRefractory disease, relapsed disease with TKI intolerance, or relapse after hematopoietic stem cell transplant
    Documentation Required

    Document TKI Failure for Ph-Positive ALL

    For Philadelphia chromosome-positive B-cell ALL, document that the member has had at least two relapses and failed at least two tyrosine kinase inhibitors when this pathway is used for eligibility.

    • Examples of TKIs include asciminib, bosutinib, dasatinib, imatinib, nilotinib, and ponatinib.
    Documentation Required

    Clinical and Laboratory Documentation

    Submit chart notes or medical-record documentation demonstrating failure of previous lines of therapy, along with disease-specific testing required for the requested indication.

    • For ALL: testing confirming CD19 tumor expression in bone marrow or peripheral blood and at least 5% lymphoblasts in bone marrow.
    • For CD19-positive ALK-positive large B-cell lymphoma: pathology or testing confirming ALK positivity and CD19 tumor expression.
    Denial Risk

    Listed Clinical Exclusions

    Coverage will not be provided when any listed clinical exclusion is present.

    • Previous treatment with Kymriah or another CD19-directed CAR T-cell therapy.
    • Inadequate or unstable kidney, liver, pulmonary, or cardiac function.
    • Active or latent hepatitis B; active hepatitis C; or any active, uncontrolled infection.
    • Active graft-versus-host disease.
    • Active inflammatory disorder.
    Denial Risk

    Noncovered and Unlisted Indications

    Primary CNS lymphoma is not an indicated use. All other uses that are not FDA-approved or listed as covered compendial uses are considered experimental/investigational and not medically necessary.

    • Listed compendial uses include pediatric B-cell ALL first relapse after HSCT, histologic transformation of indolent lymphoma to DLBCL, HIV-related B-cell lymphomas, monomorphic post-transplant lymphoproliferative disorder, CD19-positive ALK-positive large B-cell lymphoma, and histologic (Richter) transformation to DLBCL.
    Denial Risk

    Primary CNS Lymphoma Exclusion

    Do not submit Kymriah for treatment of primary central nervous system lymphoma; this indication is specifically excluded from coverage.

    Documentation Required

    Prior Treatment and Disease Eligibility

    For covered adult B-cell lymphoma indications, document prior treatment with two or more lines of systemic therapy. Covered disease categories include DLBCL, high-grade B-cell lymphoma, specified HIV-related B-cell lymphomas, monomorphic post-transplant lymphoproliferative disorder, follicular lymphoma or transformation of indolent lymphoma to DLBCL, CD19-positive relapsed/refractory ALK-positive large B-cell lymphoma, and Richter transformation to DLBCL.

    • For Richter transformation, document the applicable clonal-status and CLL treatment history, including response, refractory disease, or progression on chemoimmunotherapy or prior systemic therapy.
    • Adult members must have an ECOG performance status of 0 to 2 for the listed B-cell lymphoma criteria.
    Prior Authorization

    Age and Disease Criteria

    Verify the member's age and the disease-specific requirements before requesting authorization.

    • B-cell precursor ALL: younger than 26 years, CD19-positive disease, at least 5% bone-marrow lymphoblasts, qualifying refractory/relapsed disease, and Karnofsky or Lansky performance status of at least 50%.
    • Adult B-cell lymphoma indications: age 18 years or older and the applicable covered lymphoma subtype.
    • Relapsed/refractory CD19-positive ALK-positive large B-cell lymphoma and Richter transformation to DLBCL require age 18 years or older.
    ECOG performance status 0-2
    ECOG range0 to 2
    Mobility and self-careAmbulatory and capable of all self-care
    Daily activityUnable to carry out any work activities; up and about more than 50% of waking hours
    Histologic Richter transformation to DLBCL
    DiseaseHistologic Richter transformation to diffuse large B-cell lymphoma
    Clonally unrelated or untreated CLL pathwayClonally unrelated disease, or previously untreated CLL, with partial response, refractory disease, or progression on chemoimmunotherapy
    Clonally related or unknown pathwayClonally related or unknown clonal status with previously treated CLL and partial response, refractory disease, or progression on prior systemic therapy
    Philadelphia chromosome-negative disease that is refractory or has had 2 or more relapsesRefractory or 2 or more relapses
  11. Philadelphia chromosome-positive disease

    • Applicable Ph-positive condition

      • Refractory disease
      • Two or more relapses and failure of at least 2 tyrosine kinase inhibitorsAt least 2 TKIs
      • Relapsed disease with TKI intolerance
      • Relapse after hematopoietic stem cell transplant
  12. Member has a Karnofsky performance status of at least 50% if age 16 or older, or a Lansky performance status of at least 50% if younger than 16At least 50%
  13. Initial therapy for adult B-cell lymphomas

    Authorization of 3 months for one dose may be granted when all of the following criteria are met.

    Initial adult B-cell lymphoma therapy

    • Member is 18 years of age or olderAge >=18 years
    • Qualifying B-cell lymphoma

      • Diffuse large B-cell lymphoma arising from follicular lymphoma
      • Follicular lymphoma
      • Histologic transformation of an indolent lymphoma to diffuse large B-cell lymphoma
      • Diffuse large B-cell lymphoma
      • High-grade B-cell lymphoma, including double/triple hit lymphoma or high-grade B-cell lymphoma not otherwise specified
      • HIV-related B-cell lymphoma, including HIV-related diffuse large B-cell lymphoma, primary effusion lymphoma, HHV8-positive diffuse large B-cell lymphoma not otherwise specified, or plasmablastic lymphoma
      • Monomorphic post-transplant lymphoproliferative disorder, B-cell type
    • Member has received prior treatment with two or more lines of systemic therapy2 or more lines
    • Member does not have primary central nervous system lymphoma
    • Member has an ECOG performance status of 0 to 2ECOG 0 to 2

    Initial therapy for ALK-positive lymphoma or Richter transformation

    Authorization of 3 months for one dose may be granted for the specified adult lymphoma indications when the applicable criteria are met.

    Other covered adult indications

    • ALK-positive large B-cell lymphoma: Member is 18 years of age or older and has relapsed or refractory ALK-positive large B-cell lymphoma that is CD19-positiveAge >=18 years; CD19-positive disease
    • Histologic Richter transformation to DLBCL: Member is 18 years of age or older and has histologic Richter transformation to diffuse large B-cell lymphoma, with either clonally unrelated disease or previously untreated chronic lymphocytic leukemia and partial response, refractory disease, or progression on chemoimmunotherapy; or clonally related or unknown clonal status after previously treated chronic lymphocytic leukemia and partial response, refractory disease, or progression on prior systemic therapyAge >=18 years

    Initial therapy

    Authorization of three months for one dose may be granted for eligible relapsed or refractory B-cell lymphoma when all of the following are met.

    Initial therapy requirements

    • Member meets an applicable covered disease indication
    • Member has received the required prior systemic therapyTwo or more prior systemic therapy lines
    • Member does not have primary central nervous system lymphoma
    • Member has an ECOG performance status of 0 to 2ECOG 0 to 2
    • For ALK-positive large B-cell lymphoma, member is at least 18 years of age and the disease is CD19-positiveAge >=18 years; CD19-positive disease